Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomer Meirson

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|December 27, 2025
Differential censoring in overall survival in phase 3 oncology clinical trialsEric J Hsu, Alexander D Sherry, Timothy A Lin, et al.
JAMA Network Open|March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural MesotheliomaTomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
Oncotarget|May 19, 2018
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitorsTomer Meirson, Alessandro Genna, Nikola Lukic, et al.
JAMA Network Open|January 22, 2025
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential CensoringTomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, et al.
Journal of Translational Medicine|December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncologyTomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Oncotarget|September 18, 2018
Tumor cell density regulates matrix metalloproteinases for enhanced migrationHasini Jayatilaka, Fatima G Umanzor, Vishwesh Shah, et al.
Journal for Immunotherapy of Cancer|May 15, 2021
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapyAbraham Nissani, Shaked Lev-Ari, Tomer Meirson, et al.
Cells|November 8, 2019
Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and ActivationLiat Ninio, Abraham Nissani, Tomer Meirson, et al.
JAMA Network Open|March 28, 2024
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020Alexander D Sherry, Andrew W Hahn, Zachary R McCaw, et al.
Microbiology Spectrum|October 31, 2022
HCV Infection Increases the Expression of ACE2 Receptor, Leading to Enhanced Entry of Both HCV and SARS-CoV-2 into Hepatocytes and a Coinfection StateTom Domovitz, Samer Ayoub, Michal Werbner, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|December 27, 2025
Differential censoring in overall survival in phase 3 oncology clinical trialsEric J Hsu, Alexander D Sherry, Timothy A Lin, et al.
JAMA Network Open|March 9, 2022
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural MesotheliomaTomer Meirson, Francesca Pentimalli, Francesco Cerza, et al.
Oncotarget|May 19, 2018
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitorsTomer Meirson, Alessandro Genna, Nikola Lukic, et al.
JAMA Network Open|January 22, 2025
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential CensoringTomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, et al.
Journal of Translational Medicine|December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncologyTomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Oncotarget|September 18, 2018
Tumor cell density regulates matrix metalloproteinases for enhanced migrationHasini Jayatilaka, Fatima G Umanzor, Vishwesh Shah, et al.
Journal for Immunotherapy of Cancer|May 15, 2021
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapyAbraham Nissani, Shaked Lev-Ari, Tomer Meirson, et al.
Cells|November 8, 2019
Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and ActivationLiat Ninio, Abraham Nissani, Tomer Meirson, et al.
JAMA Network Open|March 28, 2024
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020Alexander D Sherry, Andrew W Hahn, Zachary R McCaw, et al.
Microbiology Spectrum|October 31, 2022
HCV Infection Increases the Expression of ACE2 Receptor, Leading to Enhanced Entry of Both HCV and SARS-CoV-2 into Hepatocytes and a Coinfection StateTom Domovitz, Samer Ayoub, Michal Werbner, et al.
Pageof 6